Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.
Other equities analysts also recently issued research reports about the stock. Royal Bank Of Canada reissued a “buy” rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Jefferies Group reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $17.33.
Shares of Karyopharm Therapeutics (KPTI) traded up $0.30 during mid-day trading on Thursday, hitting $10.63. 138,455 shares of the stock were exchanged, compared to its average volume of 234,601. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. sell-side analysts forecast that Karyopharm Therapeutics will post -2.59 earnings per share for the current year.
In other news, SVP Christopher Brett Primiano sold 4,958 shares of Karyopharm Therapeutics stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mansoor Raza Mirza sold 2,882 shares of Karyopharm Therapeutics stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the transaction, the director now directly owns 2,882 shares of the company’s stock, valued at $31,702. The disclosure for this sale can be found here. Insiders sold a total of 13,458 shares of company stock valued at $152,778 over the last ninety days. Company insiders own 14.71% of the company’s stock.
A number of institutional investors have recently bought and sold shares of KPTI. Voya Investment Management LLC lifted its stake in shares of Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after acquiring an additional 4,444 shares during the period. Tudor Investment Corp ET AL acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $136,000. Trexquant Investment LP acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $202,000. State of Wisconsin Investment Board acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $235,000. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Karyopharm Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after acquiring an additional 5,586 shares during the period. 60.92% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/08/karyopharm-therapeutics-kpti-downgraded-by-bidaskclub-to-sell.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.